logo
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update

Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update

Business Wire13-05-2025

LYON, France--(BUSINESS WIRE)--Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today reported its revenue for the quarter ended March 31, 2025 and provided corporate update.
Thomas Kuhn, Chief Executive Officer of Poxel, stated: 'TWYMEEG ® has further demonstrated its strong potential in FY 2024 1 with the commercial performance in Japan representing a 65% increase over FY 2023. This robust growth is expected to continue in FY 2025 and beyond, and should be further strengthened driven by a number of key recent milestones, including the recent regulatory approval in Japan allowing TWYMEEG ® to be prescribed to type 2 diabetic patients with moderate to severe renal impairment, a key patient population, particularly elderly individuals with renal impairment, who are faced with limited treatment options. In parallel of these achievements, our top priority remains to secure a path forward for the Company. We continue to be actively engaged in discussions with our creditors with the aim of reaching a structuring solution that would ensure the continuity of the Company's operations, and with potential partners to develop strategic opportunities to unlock the value of our pipeline of products.'
Commercial and Clinical Update
TWYMEEG ® (Imeglimin)
For the quarter ended March 2025, TWYMEEG ® gross sales in Japan totalled JPY 1.9 billion (EUR 12 million) 2. As a result, for Sumitomo Pharma's FY 2024 1, TWYMEEG ® gross sales reached JPY 7.6 billion (EUR 47.1 million) 2, in line with Sumitomo Pharma's most recent FY 2024 guidance (JPY 7.9 billion) and representing an increase by 65% over FY 2023.
For its FY 2025 5, Sumitomo Pharma forecasts gross sales for TWYMEEG ® of JPY 11.2 billion 4 (EUR 69.4 million) 2 which would represent a 47% increase over FY 2024 TWYMEEG ® gross sales. This forecast includes an incremental uptake among type 2 diabetic patients with renal impairment following the recent approval by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to revise TWYMEEG ® package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m 2.
Based on this FY 2025 forecast, TWYMEEG ® could reach JPY 10 billion net sales (EUR 62 million) 2 entitling Poxel to receive 12% royalties on all TWYMEEG ® net sales and a second sales-based payment of JPY 1 billion (EUR 6.3 million) 2. Following the recent royalty monetization agreement with OrbiMed, these proceeds will go exclusively towards the reimbursement of the bonds issuance. Beyond 2025, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.
In August 2024, topline results from the post-marketing clinical study, TWINKLE (TW YMEEG ® in d i abetic patients with re n al impairment: A post-mar k eting l ong-t e rm study) conducted by Sumitomo Pharma in Japanese type 2 diabetic patients with renal impairment confirmed TWYMEEG ® 's safety and tolerability profile, which is consistent with prior clinical studies. Based on these results, Sumitomo Pharma led discussions with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan leading to the revision of TWYMEEG ® package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m 2 on April 8, 2025. This approval has enabled Sumitomo Pharma to immediately start promoting the use of TWYMEEG ® in this population.
This regulatory milestone builds on the recently granted patent (n°7635474) by the Japanese Patent Office to Poxel 6 covering the use of Imeglimin in type 2 diabetic patients with moderate to severe renal impairment until 2039, strengthening TWYMEEG ® 's patent portfolio in Japan and protecting its use in this population. Poxel previously received the grant of this patent in China 7, the world's second largest type 2 diabetes market, further supporting ongoing discussions initiated by the Company to develop Imeglimin beyond Japan.
PXL065
On March 20, 2025, positive top-line results for PXL065 were obtained from a preclinical study conducted in a mouse model of hypertrophic cardiomyopathy (HCM), the most common genetic cardiac disorder. The preclinical study was financed through a grant by DZHK 8 and conducted at the TUM University Hospital German Heart Center under a research collaboration. After 10 weeks of treatment, a significant reduction in myocardial hypertrophy associated with a significant reduction in cardiac fibrosis was demonstrated, highlighting the potential of PXL065 in this pathology. These results further support the clinical development of PXL065 as a potential disease-modifying treatment for symptomatic and asymptomatic HCM and will be presented at a future scientific meeting.
First Quarter 2025 Consolidated Revenue
Poxel reported EUR 1,066 thousand 2 consolidated revenue for the quarter ended March 31, 2025, representing a 137% increase compared to the 2024 Q1 revenue.
Consolidated revenue for the first quarter of 2025 reflects JPY 172 million (EUR 1,066 thousand 2) of royalty revenue from Sumitomo Pharma, which represents 10% of TWYMEEG ® net sales in Japan. Based on the current forecast, Poxel expects to receive at least 12% royalties on TWYMEEG ® net sales in Japan through the Sumitomo Pharma fiscal year 2025 5. As part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of Imeglimin, independent of the level of sales. According to the Royalty Monetization agreement with OrbiMed, the positive net Royalties will be fully dedicated to the repayment of the bonds.
Update on existing event of default under the IRIS and IPF Partners existing bond financing agreements and search of structuring financial solution to ensure the continuity of the Company
Since the announcement by the Company of the events of default under the IRIS and IPF Partners outstanding bond financing agreements triggered by the non-adoption of the financial delegations at the Combined General Meeting held on February 11, 2025, the Board of Directors and the Management of Poxel continue to actively negotiate with the Company's creditors, with the aim of reaching a structuring solution that would ensure the continuity of the Company's operations. As announced on April 16, 2025, Poxel's financial outlook remains highly constrained with a cash runway currently estimated through June 2025, depending on the outcome of current discussions with the Company's creditors.
In parallel, the Company is also progressing discussions with several potential partners for the development of its pipeline products.
As already announced on April 16, 2025, given the potential impact on the Company's financial statements of the negotiations with the Company's creditors and potential partners, Poxel has postponed the approval and publication of its 2024 Full-Year Results. A new date will be communicated once these negotiations are finalized.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R -pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG ® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 'target,' 'believe,' 'expect,' 'aim,' 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
Glossary
You will find below a list of words and/or expressions that are used in this press release or in Poxel's communication, with the aim of bringing clarification and transparency:
Sumitomo Pharma fiscal year runs April to March. As an example, Fiscal Year 2024 is April 1, 2024, through March 31, 2025.
TWYMEEG ® royalties: As per the Sumitomo Pharma's agreement, Poxel is entitled to receive royalties from the sales of TWYMEEG ® (Imeglimin) in Japan
Sumitomo Pharma communicates gross sales of TWYMEEG ®, while TWYMEEG ® royalties are calculated on net sales.
Net sales represent the amount of gross sales to which are deducted potential rebates, allowances, and costs such as prepaid freight, postage, shipping, customs duties and insurance charges.
Poxel is entitled to receive escalating royalties of 8-18% on TWYMEEG ® net sales from Sumitomo Pharma.
Positive net royalties: as part of the Merck Serono licensing agreement, Poxel will pay Merck Serono a fixed 8% royalty based on the net sales of TWYMEEG ®, independent of the level of sales. All royalties that Poxel receives from TWYMEEG ® net sales above that 8% level are considered as positive net royalties. Net royalties will therefore be positive for Poxel when TWYMEEG ® net sales exceed JPY 5 billion in a fiscal year and royalties reach 10% and above.
Poxel refers to the Group Poxel, including its affiliates (Poxel Inc. and Poxel KK) as well as the 3 security trusts set up as part of the Royalty monetization and debt restructuring operations announced on September 30, 2024.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month
Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month

Business Wire

time24 minutes ago

  • Business Wire

Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA). Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health. We're making it now effective and affordable to many patients in the US. No need for insurance! Share More than 50 million Americans suffer from OSA, yet 80% remain untreated, and many who start CPAP therapy abandon it due to discomfort. The iNAP system offers a new path forward. 'The OSA treatment landscape is no longer CPAP-only. iNAP is effective, comfortable, and discreet—and now, more affordable than ever,' said Olivier Lauzeral, General Manager of Somnics Health. 'With iNAP Essentials, we're removing the affordability hurdle.' A Smarter, Simpler Solution iNAP is an FDA-cleared, clinically validated therapy that uses gentle negative pressure to keep the airway open during sleep—without forcing air through a mask. It works by creating a light vacuum in the oral cavity, shifting soft tissues forward and preventing obstruction. Key benefits include: No mask, no noise, no forced air Compact and travel-friendly Rechargeable battery lasting up to 5 nights Patients appreciate the freedom and discretion the iNAP system offers, particularly for travel and daily life. 'Adherence is one of iNAP's biggest strengths,' added Lauzeral. 'When therapy fits into your life instead of disrupting it, patients stay with it—and that's how we win against OSA.' What's Included in iNAP Essentials For $58/month for 24 months, iNAP Essentials includes: A full iNAP Starter Kit 3 months of supplies (mouthpiece, tubing) Free nationwide shipping Personalized onboarding with a trained iNAP Sleep Coach Access to the iNAP Sleep App for tracking progress and sharing data with providers After the initial supply period, patients can purchase refills as needed from Somnics' online store—offering flexibility without hidden fees or long-term commitments. 'We built this program with transparency and simplicity at its core,' said Lauzeral. 'It's everything you need to start treatment—nothing you don't.' Addressing a Changing Market While CPAP has long dominated the OSA space, patient dissatisfaction is driving demand for alternatives like oral appliances, positional therapy, and implantable devices. Many of these, however, are costly, invasive, or hard to access. iNAP stands out as non-invasive, portable, and now financially accessible. Clinical studies show iNAP can significantly reduce AHI, with outcomes on par with CPAP—but with higher comfort and adherence. More Ways to Access iNAP For patients who prefer to own their device upfront, Somnics has partnered with Affirm® to offer interest-free installment plans. 'Some patients want to purchase the device outright. With Affirm, they can do that without financial strain,' said Lauzeral. Provider-Guided, Patient-Focused iNAP is available by prescription only, ensuring medical oversight from a sleep specialist. Adoption is growing across VA hospitals, sleep centers, and DME providers. 'Physicians are seeing the value of iNAP in improving adherence and patient satisfaction,' Lauzeral emphasized. 'When patients feel empowered, they stay engaged—and that's the future of sleep medicine.' Advancing Health Equity Untreated sleep apnea increases the risk of heart disease, stroke, diabetes, and cognitive decline. Somnics Health sees iNAP Essentials not just as a product offering—but as a public health solution. 'This isn't just about access—it's about fairness,' said Lauzeral. 'Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health.' About Somnics Health Somnics Health is a medical device company focused on advancing patient-centric solutions for sleep-disordered breathing. Its flagship product, iNAP Sleep Therapy, helps patients treat OSA without the discomfort of traditional therapies. With offices in California and Taiwan, Somnics continues to lead in innovation, education, and patient adherence.

IFF Appoints Virginia "Gina" Drosos to Board of Directors
IFF Appoints Virginia "Gina" Drosos to Board of Directors

Yahoo

time25 minutes ago

  • Yahoo

IFF Appoints Virginia "Gina" Drosos to Board of Directors

NEW YORK, June 09, 2025--(BUSINESS WIRE)--IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world's largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experience. Gina also spent 25 years at Procter & Gamble (NYSE: PG)—most recently as group president of global beauty, skin, cosmetics and personal care—where she established herself as a transformative, purpose-led leader who drove game-changing innovation, built multi-billion-dollar brands and reinvented global categories. She currently serves as a director of Foot Locker Inc. and the United States Golf Association and previously served as a board member of American Financial Group, Inc., where she served on the audit and governance committees. "I'm honored to join the IFF board at such a pivotal time in the company's journey," said Drosos. "IFF's commitment to innovation, sustainability and purpose-driven growth deeply resonates with me. I look forward to contributing to the company's long-term strategy and helping shape its future as a global leader in food and beverage, home and personal care and health and wellness solutions." Cautionary Statement under the Private Securities Litigation Reform Act of 1995 This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as ""plan", "expect," "anticipate," "intend," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the new facilities. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on Contacts Media Relations:Paulina Investor Relations:Michael Sign in to access your portfolio

IFF Appoints Virginia 'Gina' Drosos to Board of Directors
IFF Appoints Virginia 'Gina' Drosos to Board of Directors

Business Wire

time30 minutes ago

  • Business Wire

IFF Appoints Virginia 'Gina' Drosos to Board of Directors

NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. 'We are very pleased to welcome Gina to the IFF board,' said Kevin O'Byrne, chair of the board. 'Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.' Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world's largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experience. Gina also spent 25 years at Procter & Gamble (NYSE: PG)—most recently as group president of global beauty, skin, cosmetics and personal care—where she established herself as a transformative, purpose-led leader who drove game-changing innovation, built multi-billion-dollar brands and reinvented global categories. She currently serves as a director of Foot Locker Inc. and the United States Golf Association and previously served as a board member of American Financial Group, Inc., where she served on the audit and governance committees. 'I'm honored to join the IFF board at such a pivotal time in the company's journey,' said Drosos. 'IFF's commitment to innovation, sustainability and purpose-driven growth deeply resonates with me. I look forward to contributing to the company's long-term strategy and helping shape its future as a global leader in food and beverage, home and personal care and health and wellness solutions.' Cautionary Statement under the Private Securities Litigation Reform Act of 1995 This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as ''plan', 'expect,' 'anticipate,' 'intend,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the new facilities. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store